PL2262831T3 - Przeciwciała przeciwko properdynie - Google Patents

Przeciwciała przeciwko properdynie

Info

Publication number
PL2262831T3
PL2262831T3 PL08772137T PL08772137T PL2262831T3 PL 2262831 T3 PL2262831 T3 PL 2262831T3 PL 08772137 T PL08772137 T PL 08772137T PL 08772137 T PL08772137 T PL 08772137T PL 2262831 T3 PL2262831 T3 PL 2262831T3
Authority
PL
Poland
Prior art keywords
properdin antibodies
properdin
antibodies
Prior art date
Application number
PL08772137T
Other languages
English (en)
Other versions
PL2262831T4 (pl
Inventor
Rekha Bansal
Original Assignee
Novelmed Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelmed Therapeutics Inc filed Critical Novelmed Therapeutics Inc
Publication of PL2262831T4 publication Critical patent/PL2262831T4/pl
Publication of PL2262831T3 publication Critical patent/PL2262831T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
PL08772137T 2008-03-03 2008-06-27 Przeciwciała przeciwko properdynie PL2262831T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3312708P 2008-03-03 2008-03-03
PCT/US2008/068530 WO2009110918A1 (en) 2008-03-03 2008-06-27 Anti-properdin antibodies
EP08772137.9A EP2262831B1 (en) 2008-03-03 2008-06-27 Anti-properdin antibodies

Publications (2)

Publication Number Publication Date
PL2262831T4 PL2262831T4 (pl) 2015-08-31
PL2262831T3 true PL2262831T3 (pl) 2015-08-31

Family

ID=41056304

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08772137T PL2262831T3 (pl) 2008-03-03 2008-06-27 Przeciwciała przeciwko properdynie

Country Status (11)

Country Link
US (1) US8435512B2 (pl)
EP (1) EP2262831B1 (pl)
AU (1) AU2008351988B2 (pl)
CY (1) CY1116488T1 (pl)
DK (1) DK2262831T3 (pl)
ES (1) ES2538114T3 (pl)
HR (1) HRP20150434T1 (pl)
PL (1) PL2262831T3 (pl)
PT (1) PT2262831E (pl)
SI (1) SI2262831T1 (pl)
WO (1) WO2009110918A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
EP2453906A4 (en) 2009-07-02 2014-01-15 Musc Found For Res Dev METHOD FOR STIMULATING THE LIVER REGENERATION
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
AU2011223660B2 (en) * 2010-03-02 2016-10-13 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin
EP2545075B1 (en) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
CA2799192A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
ES2701075T3 (es) * 2011-07-01 2019-02-20 Univ Pennsylvania Anticuerpos antiproperdina y usos de estos
SG11201403416TA (en) * 2011-12-21 2014-07-30 Novartis Ag Compositions and methods for antibodies targeting factor p
CA2862448A1 (en) * 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
EP3011345B1 (en) 2013-08-07 2017-10-04 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
JP6643244B2 (ja) * 2014-02-27 2020-02-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体
EP3274724A1 (en) * 2015-03-25 2018-01-31 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
GB2553252B (en) 2016-01-20 2019-07-31 Vitrisa Therapeutics Inc Aptamers that block the catalytic cleft of complement Factor D
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
KR102613874B1 (ko) * 2017-01-30 2023-12-15 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편
JP2020532285A (ja) 2017-07-11 2020-11-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
WO2021140475A1 (en) * 2020-01-08 2021-07-15 Cadila Healthcare Limited Anti-properdin antibodies and preparation thereof
JP2023536737A (ja) 2020-08-04 2023-08-29 アボット・ラピッド・ダイアグノスティクス・インターナショナル・アンリミテッド・カンパニー Ｓａｒｓ－ｃｏｖ－２を検出するためのアッセイ
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335511T1 (de) * 1997-08-26 2006-09-15 Amgen Fremont Inc Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
AU2003212475A1 (en) * 2002-03-01 2003-09-16 Incyte Corporation Immune response associated proteins
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
WO2006128006A1 (en) * 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
WO2008154018A2 (en) * 2007-06-11 2008-12-18 The Trustees Of The University Of Pennsylvania Properdin modulation of alternative pathway and uses thereof

Also Published As

Publication number Publication date
EP2262831A1 (en) 2010-12-22
US20110008340A1 (en) 2011-01-13
CY1116488T1 (el) 2017-03-15
WO2009110918A1 (en) 2009-09-11
HRP20150434T1 (hr) 2015-06-05
AU2008351988A1 (en) 2009-09-11
PL2262831T4 (pl) 2015-08-31
PT2262831E (pt) 2015-05-18
US8435512B2 (en) 2013-05-07
DK2262831T3 (en) 2015-04-27
EP2262831A4 (en) 2012-07-25
SI2262831T1 (sl) 2015-10-30
ES2538114T3 (es) 2015-06-17
EP2262831B1 (en) 2015-01-21
AU2008351988B2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
EP2262831A4 (en) ANTI-properdin antibody
ZA201005348B (en) Humanized anti-c5ar antibodies
AP3371A (en) Anti-IGF antibodies
ZA201102119B (en) Improved antibody libraies
IL214996A0 (en) Anti-bcma antibodies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
GB0920127D0 (en) Antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
IL212701A0 (en) Improved anti-cd19 antibodies
GB0821100D0 (en) Antibodies
GB0909906D0 (en) Antibodies
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
IL236236A (en) Antibodies to the fam26f polypeptide
ZA201006099B (en) Anti-tyrp1 antibodies
GB0920324D0 (en) Antibodies
HK1170745A1 (en) Antibodies against il-17br il-17br
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
GB0911770D0 (en) Antibody
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies
GB0817621D0 (en) Antibody